Related Experiment Video
Updated: Jun 5, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
GLP-1 agonists versus bariatric surgery: Which management carries heavier weight prior to total knee arthroplasty?
Christine L Zickler1, Samuel P Alfonsi1, Omar S Shalakthi1
1Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Purpose:
Both glucagon-like peptide-1 (GLP-1) receptor agonists and bariatric surgery (BS) are interventions that result in weight loss prior to total knee arthroplasty (TKA). We sought to compare 90-day postoperative complications between TKA patients with a history of GLP-1 use versus those who underwent BS prior to TKA.
Methods:
Patients undergoing primary TKA for osteoarthritis from 2005 to 2025 were identified from the TriNetX Research Network. Patients who underwent BS 6 months to 1 year prior to TKA were propensity score-matched 1:1 to patients who initiated GLP-1 therapy during this same time period based on age, sex, race, chronic kidney disease, rheumatoid arthritis, hypertension, heart disease, diabetes and body mass index (BMI) measured 6 weeks prior to weight-loss intervention. A total of 1650 patients were included in each cohort with 90-day follow-up. The risk of various 90-day complications associated with each weight-loss intervention was compared utilizing univariate analyses.
Results:
Rates of individual medical and surgical complications were largely comparable between cohorts; however, compared with the BS group, the GLP-1 cohort had significantly lower rates of deep vein thrombosis/pulmonary embolus (2.18% vs. 4.42%, p < 0.001), transfusion (0.30% vs. 1.03%, p = 0.016), any surgical complication (1.64% vs. 3.45%, p = 0.001), any medical complication (9.09% vs. 12.30%, p = 0.003) and readmission/emergency department visit (21.33% vs. 25.33%, p = 0.007). Compared to obese controls without intervention prior to TKA, both the BS and GLP-1 cohorts had comparable rates of all medical and surgical complications.
Conclusions:
There were largely comparable rates of complications between patients who underwent BS and those who initiated GLP-1 agonists prior to TKA, although GLP-1 use was associated with lower rates of select complications. Patients who choose GLP-1 agonists or BS can expect similar complication rates and comparable outcomes relative to obese patients who elect for no preoperative intervention prior to TKA.
Level Of Evidence:
Level III, retrospective cohort study.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:

